Can growth hormone counteract the catabolic effects of steroids?

Hormone Research

Volumn 72, Issue SUPPL. 1, 2009, Pages 48-54

  Mauras, Nelly ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

Catabolic effects; Growth hormone; IGF I

Indexed keywords

GLUCOCORTICOID; GLUTAMINE; GROWTH HORMONE; GROWTH HORMONE RECEPTOR; INSULIN RECEPTOR; JANUS KINASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYOGENIN; MYOSTATIN; SOMATOMEDIN C; STAT PROTEIN; TRANSCRIPTION FACTOR FOXO;

ARTICLE; BODY COMPOSITION; BODY MASS; BONE GROWTH; CARBOHYDRATE METABOLISM; CATABOLISM; CHILD; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG EFFECT; ENTERITIS; GENETIC TRANSCRIPTION; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; GROWTH RETARDATION; HORMONAL THERAPY; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; HYPERINSULINEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; JUVENILE RHEUMATOID ARTHRITIS; LARON SYNDROME; LEAN BODY WEIGHT; LIPID METABOLISM; MUSCLE ATROPHY; MUSCLE DEVELOPMENT; OSSIFICATION; OSTEOLYSIS; PRADER WILLI SYNDROME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANABOLIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; BODY COMPOSITION; CARBOHYDRATE METABOLISM; CHILD; CYSTIC FIBROSIS; GLUCOCORTICOIDS; GROWTH; GROWTH DISORDERS; GROWTH HORMONE; HUMANS; INFLAMMATORY BOWEL DISEASES; INSULIN-LIKE GROWTH FACTOR I; LIPID METABOLISM; MUSCLE PROTEINS;

EID: 73649127983     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000229764     Document Type: Article

References (43)

1. Schakman O, Gilson H, Thissen JP: Mechanisms of glucocorticoid-induced myopathy. J Endocrinol 2008; 197: 1-10
2. Beaufrere B, Horber FF, Schwenk WF, Marsh HM, Matthews D, Gerich JE, Haymond MW: Glucocorticosteroids increase leucine oxidation and impair leucine balance in humans. Am J Physiol 1989; 257:E712-E721
3. Mayo-Smith W, Hayes CW, Biller BMK, Klibanski A, Rosenthal H, Rosenthal DI: Body fat distribution measured with CT: correlations in healthy subjects, patients with anorexia nervosa, and patients with Cushing syndrome. Radiology 1989; 170: 515-518
4. Rosenfeld R, Reiter EO: Normal and aberrant growth; in Kronenberg HM, Melmed S, Polonsky KS, Larsen PR (eds): Williams Textbook of Endocrinology, 2008, ed 11. Philadelphia, Saunders, pp 849-968
5. Greenhalgh CJ, Alexander WS: Suppressors of cytokine signalling and regulation of growth hormone action. Growth Horm IGF Res 2004; 14: 200-206
6. Metcalf D, Greenhalgh CJ, Viney E, Willson TA, Starr R, Nicola NA, Hilton DJ, Alexander WS: Gigantism in mice lacking suppressor of cytokine signalling-2. Nature 2000; 405: 1069-1073
7. Rinderknecht E, Humbel RE: The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769-2776
8. Werner H, Woloschak M, Stannard B, Shen-Orr A, Roberts CT Jr, LeRoith D: The insulin-like growth factor I receptor: molecular biology, heterogeneity, and regulation; in Le-Roith D (ed): Insulin-Like Growth Factors: Molecular and Cellular Aspects. Boca Raton, CRC Press, 1991, pp 17-47
9. Di Cola G, Cool MH, Accili D: Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors. J Clin Invest 1997; 99: 2538-2544
10. Mauras N, Haymond MW: Are the metabolic effects of GH and IGF-I separable? Growth Horm IGF Res 2005; 15: 19-27
11. Mauras N, O'Brien KO, Welch S, Rini A, Helgeson K, Vieira NE, Yergey AL: Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid and calcium metabolism. J Clin Endocrinol Metab 2000; 85: 1686-1694 (Pubitemid 32289519)
12. Mauras N, Bishop K, Welch S: Growth hormone action in puberty: effects by gender. Growth Horm IGF Res 2007; 17: 463-471
13. Kupfer SR, Underwood LE, Baxter RC, Clemmons DR: Enhancement of the anabolic effects of growth hormone and insulinlike growth factor I by use of both agents simultaneously. J Clin Invest 1993; 91: 391-396
14. Mauras N: Combined recombinant human growth hormone and recombinant human insulin-like growth factor I: lack of synergy on whole body protein anabolism in normally fed subjects. J Clin Endocrinol Metab 1995; 80: 2633-2637
15. Mauras N, Martinez V, Rini A, Guevara-Aguirre J: Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism. J Clin Endocrinol Metab 2000; 85: 3036-3042
16. Saenger P, Attie KM, Dimartino-Nardi J, Hintz R, Frahm L, Frane JW: Metabolic consequences of 5-year growth hormone (GH) therapy in children treated with GH for idiopathic short stature. Genentech Collaborative Study Group. J Clin Endocrinol Metab 1998; 83: 3115-3120
17. Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB: Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997; 350: 1199-1204
18. DiGirolamo M, Edén S, Enberg G, Isaksson O, Lönnroth P, Hall K, Smith U: Specific binding of human growth hormone but not insulin-like growth factors by human adipocytes. FEBS Lett 1986; 205: 15-19
19. Vance ML, Mauras N: Growth hormone therapy in adults and children. N Engl J Med 1999; 341: 1206-1216
20. Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sönksen PH, Tanaka T, Thorne M: Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 1998; 83: 382-395 (Pubitemid 28496511)
21. Beauville M, Harant I, Crampes F, Riviere D, Tauber MT, Tauber JP, Garrigues M: Effect of long-term rhGH administration in GHdeficient adults on fat cell epinephrine response. Am J Physiol 1992; 263:E467-E472
22. Yang S, Björntorp P, Liu X, Edén S: Growth hormone treatment of hypophysectomized rats increases catecholamine-induced lipolysis and the number of adrenergic receptors in adipocytes: no differences in the effects of GH on different fat depots. Obes Res 1996; 4: 471-478
23. Marcus C, Bolme P, Micha-Johansson G, Margery V, Brönnegård M: Growth hormone increases the lipolytic sensitivity for catecholamines in adipocytes from healthy adults. Life Sci 1994; 54: 1335-1341
24. Rudling M, Norstedt G, Olivecrona H, Reihner E, Gustafsson JA, Angelin B: Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc Natl Acad Sci USA 1992; 89: 6983-6987
25. Mauras N: Metabolic effects of insulin-like growth factor I and growth hormone in vivo: a comparison; in Le Roith D, Zumkeller W, Baxter RC (eds): Insulin-Like Growth Factor Receptor Signalling. New York, Kluwer Academic Plenum Publishers, 2003, pp 423-433
26. Rosenbaum M, Gertner JM, Leibel RL: Effects of systemic growth hormone (GH) administration on regional adipose tissue distribution and metabolism in GH-deficient children. J Clin Endocrinol Metab 1989; 69: 1274-1281
27. Myers SE, Carrel AL, Whitman BY, Allen DB: Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. J Pediatr 2000; 137: 42-49
28. Friedlander AL, Butterfield GE, Moynihan S, Grillo J, Pollack M, Holloway L, Friedman L, Yesavage J, Matthias D, Lee S, Marcus R, Hoffman AR: One year of insulin-like growth factor I treatment does not affect bone density, body composition, or psychological measures in postmenopausal women. J Clin Endocrinol Metab 2001; 86: 1496-1503
29. Kaufmann S, Jones KL, Wehrenberg WB, Culler FL: Inhibition by prednisone of growth hormone (GH) response to GH-releasing hormone in normal men. J Clin Endocrinol Metab 1988; 67: 1258-1261
30. Miell JP, Corder R, Pralong FP, Gaillard RC: Effects of dexamethasone on growth hormone (GH)-releasing hormone, arginineand dopaminergic stimulated GH secretion, and total plasma insulin-like growth factor-I concentrations in normal male volunteers. J Clin Endocrinol Metab 1991; 72: 675-681
31. Kritsch KR, Murali S, Adamo ML, Ney DM: Dexamethasone decreases serum and liver IGF-I and maintains liver IGF-I mRNA in parenterally fed rats. Am J Physiol Regul Integr Comp Physiol 2002; 282:R528-R536
32. Smink JJ, Gresnigt MG, Hamers N, Koedam JA, Berger R, Van Buul-Offers SC: Shortterm glucocorticoid treatment of prepubertal mice decreases growth and IGF-I expression in the growth plate. J Endocrinol 2003; 177: 381-388
33. Mehls O, Himmele R, Hömme M, Kiepe D, Klaus G: The interaction of glucocorticoids with the growth hormone-insulin-like growth factor axis and its effects on growth plate chondrocytes and bone cells. J Pediatr Endocrinol Metab 2001; 14(suppl 6):1475-1482
34. Horber FF, Haymond MW: Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990; 86: 265-272
35. Horber FF, Marsh HM, Haymond MW: Differential effects of prednisone and growth hormone on fuel metabolism and insulin antagonism in humans. Diabetes 1991; 40: 141-149
36. Mauras N, Beaufrere B: Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect. J Clin Endocrinol Metab 1995; 80: 869-874
37. Ortoft G, Andreassen TT, Oxlund H: Growth hormone increases cortical and cancellous bone mass in young growing rats with glucocorticoid-induced osteopenia. J Bone Miner Res 1999; 14: 710-721
38. Ortoft G, Andreassen TT, Oxlund H: Growth hormone can reverse glucocorticoid-induced low bone turnover on cortical but not on cancellous bone surfaces in adult Wistar rats. Bone 2005; 36: 123-133
39. Mauras N, George D, Evans J, Milov D, Abrams S, Rini A, Welch S, Haymond MW: Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metabolism 2002; 51: 127-135
40. Lai HC, FitzSimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, Farrell PM: Risk of persistent growth impairment after alternate-day prednisone treatment in children with cystic fibrosis. N Engl J Med 2000; 342: 851-859
41. Darmaun D, Hayes V, Schaeffer D, Welch S, Mauras N: Effects of glutamine and recombinant human growth hormone on protein metabolism in prepubertal children with cystic fibrosis. J Clin Endocrinol Metab 2004; 89: 1146-1152
42. Hardin DS, Adams-Huet B, Brown D, Chatfield B, Dyson M, Ferkol T, Howenstine M, Prestidge C, Royce F, Rice J, Seilheimer DK, Steelman J, Shepherds R: Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. J Clin Endocrinol Metab 2006; 91: 4925-4929
43. Simon D, Prieur AM, Quartier P, Charles Ruiz J, Czernichow P: Early recombinant human growth hormone treatment in glucocorticoid-treated children with juvenile idiopathic arthritis: a 3-year randomized study. J Clin Endocrinol Metab 2007; 92: 2567-2573